tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2023 Mar 2;2184754.
doi: 10.1080/21645515.2023.2184754. Online ahead of print.
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
Xiaoying Zhou[SUP] 1 [/SUP], Huixia Lu[SUP] 2 [/SUP], Miaomiao Sang[SUP] 1 [/SUP], Shanhu Qiu[SUP] 3 [/SUP], Yang Yuan[SUP] 1 [/SUP], Tongzhi Wu[SUP] 4 [/SUP], Junhao Chen[SUP] 5 [/SUP], Zilin Sun[SUP] 1 [/SUP]
Affiliations
Abstract
Patients with type 2 diabetes (T2D) are at an increased risk of morbidity and mortality of coronavirus disease 2019 (COVID-19). Data on the antibody response to COVID-19 vaccines in T2D patients are less studied. This study aimed to evaluate IgG antibody response to inactivated COVID-19 vaccines in hospitalized T2D patients. Hospitalized patients with no history of COVID-19 and received two doses of inactivated COVID-19 vaccines (Sinopharm or CoronaVac) were included in this study from March to October 2021. SARS-CoV-2 specific IgG antibodies were measured 14-60 days after the second vaccine dose. A total of 209 participants, 96 with T2D and 113 non-diabetes patients, were included. The positive rate and median titer of IgG antibody against receptor-binding domain (anti-RBD) of spike (S) protein of SARS-CoV-2 in T2D group were lower than in control group (67.7% vs 83.2%, p = .009; 12.93 vs 17.42 AU/ml, p = .014) respectively. Similarly, seropositivity and median titers of IgG antibody against the nucleocapsid (N) and S proteins of SARS-CoV-2 (anti-N/S) in T2D group were lower than in control group (68.8% vs 83.2%, p = .032; 18.81 vs 29.57 AU/mL, p = .012) respectively. After adjustment for age, sex, BMI, vaccine type, days after the second vaccine dose, hypertension, kidney disease, and heart disease, T2D was identified as an independent risk factor for negative anti-RBD and anti-N/S seropositivity, odd ratio 0.42 (95% confidence interval 0.19, 0.89) and 0.42 (95% CI 0.20, 0.91), respectively. T2D is associated with impaired antibody response to inactivated COVID-19 vaccine.
Keywords: COVID-19; Type 2 diabetes; seropositivity; vaccine.
. 2023 Mar 2;2184754.
doi: 10.1080/21645515.2023.2184754. Online ahead of print.
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
Xiaoying Zhou[SUP] 1 [/SUP], Huixia Lu[SUP] 2 [/SUP], Miaomiao Sang[SUP] 1 [/SUP], Shanhu Qiu[SUP] 3 [/SUP], Yang Yuan[SUP] 1 [/SUP], Tongzhi Wu[SUP] 4 [/SUP], Junhao Chen[SUP] 5 [/SUP], Zilin Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 36864628
- DOI: 10.1080/21645515.2023.2184754
Abstract
Patients with type 2 diabetes (T2D) are at an increased risk of morbidity and mortality of coronavirus disease 2019 (COVID-19). Data on the antibody response to COVID-19 vaccines in T2D patients are less studied. This study aimed to evaluate IgG antibody response to inactivated COVID-19 vaccines in hospitalized T2D patients. Hospitalized patients with no history of COVID-19 and received two doses of inactivated COVID-19 vaccines (Sinopharm or CoronaVac) were included in this study from March to October 2021. SARS-CoV-2 specific IgG antibodies were measured 14-60 days after the second vaccine dose. A total of 209 participants, 96 with T2D and 113 non-diabetes patients, were included. The positive rate and median titer of IgG antibody against receptor-binding domain (anti-RBD) of spike (S) protein of SARS-CoV-2 in T2D group were lower than in control group (67.7% vs 83.2%, p = .009; 12.93 vs 17.42 AU/ml, p = .014) respectively. Similarly, seropositivity and median titers of IgG antibody against the nucleocapsid (N) and S proteins of SARS-CoV-2 (anti-N/S) in T2D group were lower than in control group (68.8% vs 83.2%, p = .032; 18.81 vs 29.57 AU/mL, p = .012) respectively. After adjustment for age, sex, BMI, vaccine type, days after the second vaccine dose, hypertension, kidney disease, and heart disease, T2D was identified as an independent risk factor for negative anti-RBD and anti-N/S seropositivity, odd ratio 0.42 (95% confidence interval 0.19, 0.89) and 0.42 (95% CI 0.20, 0.91), respectively. T2D is associated with impaired antibody response to inactivated COVID-19 vaccine.
Keywords: COVID-19; Type 2 diabetes; seropositivity; vaccine.